Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS – Get Free Report) was the target of a large decrease in short interest in the month of May. As of May 15th, there was short interest totalling 816,000 shares, a decrease of 12.0% from the April 30th total of 926,900 shares. Based on an average trading volume of 297,900 shares, […]
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) issued its quarterly earnings results on Monday. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), Zacks reports. During the same period last year, the firm posted ($0.28) earnings per share. Acumen Pharmaceuticals Stock Performance Shares of ABOS stock […]
Acumen Pharmaceuticals (NASDAQ:ABOS – Get Free Report) posted its quarterly earnings results on Monday. The company reported ($0.25) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02), Zacks reports. During the same period in the previous year, the company posted ($0.28) EPS. Acumen Pharmaceuticals Stock Down 2.4 % Acumen Pharmaceuticals stock traded […]
HC Wainwright reissued their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a report released on Wednesday, Benzinga reports. The brokerage currently has a $15.00 price target on the stock. Acumen Pharmaceuticals Stock Performance ABOS stock traded down $0.04 during trading hours on Wednesday, reaching $3.76. The stock had a trading […]
HC Wainwright restated their buy rating on shares of Acumen Pharmaceuticals (NASDAQ:ABOS – Free Report) in a research note published on Wednesday morning, Benzinga reports. The firm currently has a $15.00 target price on the stock. Acumen Pharmaceuticals Stock Performance Shares of NASDAQ ABOS traded down $0.04 during trading on Wednesday, hitting $3.76. The company […]